Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR2 | O95665 | 3/20 | 0.50 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.50 |
| ▸ | CD40 | P25942 | 2/20 | 0.49 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 2/20 | 0.47 |
| ▸ | NPY1R | P25929 | 1/20 | 0.47 |
| ▸ | NPY2R | P49146 | 1/20 | 0.47 |
| ▸ | NPY4R | P50391 | 1/20 | 0.47 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | TFPI | P10646 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30816279 | 0.93 | OPRD1 (0.49) | BACE1KISS1ROPRD1 | |
| SCHEMBL31256984 | 0.86 | BACE1 (0.60) | NTSR2NTSR1BACE1F2KISS1R | |
| SCHEMBL30168703 | 0.85 | TFPI (0.59) | F2TFPI | |
| SCHEMBL31307291 | 0.85 | KISS1R (0.53) | NTSR2NTSR1BACE1KISS1ROPRD1 | |
| SCHEMBL30900783 | 0.85 | TFPI (0.58) | KISS1ROPRD1TFPI | |
| SCHEMBL31243925 | 0.84 | TFPI (0.60) | OPRD1TFPI | |
| SCHEMBL31688303 | 0.84 | GLP1R (0.56) | OPRD1TFPI | |
| SCHEMBL29472190 | 0.84 | OPRD1 (0.54) | NTSR2NTSR1F2KISS1ROPRD1 | |
| SCHEMBL9058846 | 0.83 | OPRD1 (0.56) | NTSR2NTSR1CD40SORT1F2 | |
| SCHEMBL30708073 | 0.83 | F2 (0.58) | BACE1F2TFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049102-A1 | A PRO-MOIETY FOR FORMING A PRODRUG SELECTIVELY CLEAVED BY PROSTATE-SPECIFIC ANTIGEN (PSA) | UNIV SYDNEY (AU) | 2026-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049102-A1 | A PRO-MOIETY FOR FORMING A PRODRUG SELECTIVELY CLEAVED BY PROSTATE-SPECIFIC ANTIGEN (PSA) | FOLH1, PSAP, KLK3 | NTSR2 888/4885NTSR1 634/4885CD40 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.